{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:38:11Z","timestamp":1787312291752,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clim.2025.110560","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:40:45Z","timestamp":1751942445000},"page":"110560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Measuring efficacy for myasthenia gravis treatments: A review of biomarkers used in clinical trials"],"prefix":"10.1016","volume":"280","author":[{"given":"Taylor","family":"Wesley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callie","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clim.2025.110560_bb0005","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J. Clin. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2025.110560_bb0010","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0022-510X(09)70222-9","article-title":"Treatment of myasthenia gravis","volume":"285","author":"Barohn","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.clim.2025.110560_bb0015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.clim.2025.110560_bb0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.37349\/ent.2022.00029","article-title":"Overview of biomarkers in myasthenia gravis","author":"Afrashteh","year":"2022","journal-title":"Explor. Neuroprotect. Ther."},{"issue":"1\u20132","key":"10.1016\/j.clim.2025.110560_bb0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neurol.2018.01.377","article-title":"Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets","volume":"175","author":"Bao","year":"2019","journal-title":"Rev. Neurol. Paris"},{"issue":"2","key":"10.1016\/j.clim.2025.110560_bb0030","first-page":"32001","article-title":"A multicenter, randomized, double-blind trial of prednisolone plus azathioprine versus prednisolone plus placebo in myasthenia gravis","volume":"46","author":"Palace","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.clim.2025.110560_bb0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamaneurol.2024.0044","article-title":"Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial","volume":"81","author":"Yan","year":"2024","journal-title":"JAMA Neurol."},{"issue":"1\u20132","key":"10.1016\/j.clim.2025.110560_bb0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2008.09.033","article-title":"Terbutaline in myasthenia gravis: a pilot study","volume":"277","author":"Soliven","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"4Part-II","key":"10.1016\/j.clim.2025.110560_bb0050","first-page":"910","article-title":"Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis","volume":"38","author":"Lin","year":"2022","journal-title":"Pak. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0055","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.clim.2025.110560_bb0060","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.clim.2025.110560_bb0065","first-page":"19044","article-title":"Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis","volume":"8","author":"Qi","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"23","key":"10.1016\/j.clim.2025.110560_bb0070","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2025.110560_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","article-title":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study","volume":"119","author":"GomezMancilla","year":"2024","journal-title":"J. Clin. Neurosci."},{"issue":"12","key":"10.1016\/j.clim.2025.110560_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clim.2025.110560_bb0085","first-page":"219","article-title":"Generalized myasthenia gravis: efficacy, safety and tolerability of efgartigimod - the ADAPT trial","volume":"28","author":"Diener","year":"2021","journal-title":"Psychopharmakotherapie"},{"issue":"9","key":"10.1016\/j.clim.2025.110560_bb0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jocn.2013.11.046","article-title":"Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action","volume":"21","author":"Zhang","year":"2014","journal-title":"J. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0095","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu","year":"2023","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.clim.2025.110560_bb0100","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00415-022-11517-w","article-title":"Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT)","volume":"270","author":"Sacc\u00e0","year":"2023","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.clim.2025.110560_bb0105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.nmd.2021.05.002","article-title":"Home-based exercise in autoimmune myasthenia gravis: a randomized controlled trial","volume":"31","author":"Birnbaum","year":"2021","journal-title":"Neuromuscul. Disord."},{"issue":"16","key":"10.1016\/j.clim.2025.110560_bb0110","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0115","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"J. Clin. Apher."},{"issue":"11","key":"10.1016\/j.clim.2025.110560_bb0125","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.clim.2025.110560_bb0130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2025.110560_bb0135","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"Meriggioli","year":"2003","journal-title":"Ann. N. Acad. Sci."},{"issue":"2","key":"10.1016\/j.clim.2025.110560_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000062987","article-title":"The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis","volume":"48","author":"Munakata","year":"2002","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.clim.2025.110560_bb0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0150","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"10.1016\/j.clim.2025.110560_bb0155","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clim.2025.110560_bb0160","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.clim.2025.110560_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther. Apher. Dial."},{"issue":"2","key":"10.1016\/j.clim.2025.110560_bb0170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.clim.2025.110560_bb0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.clim.2025.110560_bb0180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"R\u00f8nager","year":"2001","journal-title":"Artif. Organs"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0185","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acn3.51946","article-title":"Subcutaneous batoclimab in generalized myasthenia gravis: results from a phase 2a trial with an open-label extension","volume":"11","author":"Nowak","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"11","key":"10.1016\/j.clim.2025.110560_bb0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0195","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"17_supplement_2","key":"10.1016\/j.clim.2025.110560_bb0200","doi-asserted-by":"crossref","first-page":"0168","DOI":"10.1212\/WNL.0000000000201793","article-title":"Serum immunoglobulin G level reduction as a predictor of short-term improvement in patients with myasthenia gravis undergoing plasmapheresis (P12-7.002)","volume":"100","author":"Konno","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23745","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Wei","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12865-022-00501-8","article-title":"Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis","volume":"23","author":"Huan","year":"2022","journal-title":"BMC Immunol."},{"issue":"7","key":"10.1016\/j.clim.2025.110560_bb0215","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/biom11070928","article-title":"Clinical and immunological biomarkers for systemic lupus erythematosus","volume":"11","author":"Yu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.clim.2025.110560_bb0220","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.15063","article-title":"Biomarkers in rheumatoid arthritis","author":"Shapiro","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23745","article-title":"Altered serum levels of cytokines in patients with myasthenia gravis","volume":"10","author":"Wei","year":"2023","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.clim.2025.110560_bb0230","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/cells11040740","article-title":"Towards personalized medicine in myasthenia gravis: role of circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p","volume":"11","author":"Beretta","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/acn3.24","article-title":"Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker","volume":"1","author":"Punga","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.clim.2025.110560_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40258-015-0198-x","article-title":"A systematic review of health economic evaluations of diagnostic biomarkers","volume":"14","author":"Oosterhoff","year":"2016","journal-title":"Appl. Health Econ. Health Policy"},{"issue":"3","key":"10.1016\/j.clim.2025.110560_bb0245","first-page":"183","article-title":"Evidence and cost effectiveness requirements for recommending new biomarkers","volume":"26","author":"Collinson","year":"2015","journal-title":"EJIFCC"},{"key":"10.1016\/j.clim.2025.110560_bb0250","doi-asserted-by":"crossref","first-page":"1247931","DOI":"10.3389\/fpubh.2023.1247931","article-title":"The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges","volume":"11","author":"Hughes","year":"2023","journal-title":"Front. Public Health"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:39:53Z","timestamp":1759862393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S1521661625001354"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110560","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring efficacy for myasthenia gravis treatments: A review of biomarkers used in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110560"}}